<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font19 { font-size : 19; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">(.) </span>
   <span class="font19">patients </span>
   <span class="font15">treatment </span>
   <span class="font15">pediatric </span>
   <span class="font13">Week </span>
   <span class="font13">sweat </span>
   <span class="font13">axillary </span>
   <span class="font13">older </span>
   <span class="font13">topical </span>
   <span class="font12">primary </span>
   <span class="font12">subgroup </span>
   <span class="font12">change </span>
   <span class="font12">{border-style </span>
   <span class="font12">ATMOS‐ </span>
   <span class="font12">hyperhidrosis </span>
   <span class="font12">px;} </span>
   <span class="font12">reported </span>
   <span class="font12">#ffffff;} </span>
   <span class="font12">Inc.; </span>
   <span class="font12">quality </span>
   <span class="font12">Inc. </span>
   <span class="font12">Resolved </span>
   <span class="font12">glycopyrronium </span>
   <span class="font12">safety </span>
   <span class="font11">Baseline </span>
   <span class="font11">GT, </span>
   <span class="font11">GT‐treated </span>
   <span class="font11">Hebert </span>
   <span class="font11">efficacy </span>
   <span class="font11">subgroups </span>
   <span class="font11">Dermira, </span>
   <span class="font11">TEAEs </span>
   <span class="font11">later </span>
   <span class="font11">life </span>
   <span class="font11">production </span>
   <span class="font11">severity </span>
   <span class="font11">Item </span>
   <span class="font11">greater </span>
   <span class="font11">hoc </span>
   <span class="font11">mouth </span>
   <span class="font11">population. </span>
   <span class="font11">responder </span>
   <span class="font11">study </span>
   <span class="font11">Glaser </span>
   <span class="font11">Mild </span>
   <span class="font11">Related </span>
   <span class="font11">anticholinergic </span>
   <span class="font11">mean </span>
   <span class="font11">measured </span>
   <span class="font11">similar </span>
   <span class="font11">trials </span>
   <span class="font11">&amp;gt; </span>
   <span class="font11">(SD) </span>
   <span class="font11">Dry </span>
   <span class="font11">Hyperhidrosis </span>
   <span class="font11">age </span>
   <span class="font11">sweating </span>
   <span class="font11">tosylate </span>
   <span class="font11">vehicle </span>
   <span class="font11">Dermatol. </span>
   <span class="font11">events </span>
   <span class="font11">observed </span>
   <span class="font11">post </span>
   <span class="font11">tosylate; </span>
   <span class="font11">(Table </span>
   <span class="font11">Dermatol </span>
   <span class="font11">Dermatology </span>
   <span class="font11">Inc., </span>
   <span class="font11">Mean </span>
   <span class="font11">Vehicle </span>
   <span class="font11">data </span>
   <span class="font11">day </span>
   <span class="font11">disease </span>
   <span class="font11">dry </span>
   <span class="font11">gravimetrically </span>
   <span class="font11">hyperhidrosis: </span>
   <span class="font11">patient </span>
   <span class="font11">production, </span>
   <span class="font11">px; </span>
   <span class="font11">randomized </span>
   <span class="font11">used </span>
   <span class="font11">vehicle‐treated </span>
   <span class="font11">years </span>
   <span class="font11">years) </span>
   <span class="font11">{font-family </span>
   <span class="font10">(Figure </span>
   <span class="font10">ASDD/ASDD‐C </span>
   <span class="font10">Completed </span>
   <span class="font10">Dr. </span>
   <span class="font10">Efficacy </span>
   <span class="font10">Figure </span>
   <span class="font10">GT‐ </span>
   <span class="font10">HDSS </span>
   <span class="font10">Medical </span>
   <span class="font10">Moderate </span>
   <span class="font10">Safety </span>
   <span class="font10">[], </span>
   <span class="font10">analysis </span>
   <span class="font10">consistent </span>
   <span class="font10">controlled </span>
   <span class="font10">findings </span>
   <span class="font10">font-size </span>
   <span class="font10">imputation </span>
   <span class="font10">investigator </span>
   <span class="font10">phase </span>
   <span class="font10">received </span>
   <span class="font10">related </span>
   <span class="font10">results </span>
   <span class="font10">(C) </span>
   <span class="font10">Intent‐to‐treat </span>
   <span class="font10">John </span>
   <span class="font10">Pariser </span>
   <span class="font10">Pediatr </span>
   <span class="font10">Severe </span>
   <span class="font10">TEAE </span>
   <span class="font10">Table </span>
   <span class="font10">Wiley </span>
   <span class="font10">adverse </span>
   <span class="font10">assessments </span>
   <span class="font10">comparisons </span>
   <span class="font10">considered </span>
   <span class="font10">designed </span>
   <span class="font10">detect </span>
   <span class="font10">double; </span>
   <span class="font10">mild, </span>
   <span class="font10">onset </span>
   <span class="font10">pooled </span>
   <span class="font10">powered </span>
   <span class="font10">proportion </span>
   <span class="font10">rates </span>
   <span class="font10">skin </span>
   <span class="font10">(%) </span>
   <span class="font10">(Item </span>
   <span class="font10">(bilateral) </span>
   <span class="font10">ASDD/ </span>
   <span class="font10">Axillary </span>
   <span class="font10">DLQI </span>
   <span class="font10">Glycopyrronium </span>
   <span class="font10">Ltd, </span>
   <span class="font10">Markov </span>
   <span class="font10">Median </span>
   <span class="font10">Monte </span>
   <span class="font10">Mydriasis </span>
   <span class="font10">P‐values </span>
   <span class="font10">Severity </span>
   <span class="font10">Sons, </span>
   <span class="font10">Study </span>
   <span class="font10">Weeks </span>
   <span class="font10">assess </span>
   <span class="font10">assessed </span>
   <span class="font10">blurred </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">calculated </span>
   <span class="font10">chain </span>
   <span class="font10">characteristics </span>
   <span class="font10">daily </span>
   <span class="font10">dermatology </span>
   <span class="font10">drug </span>
   <span class="font10">effect </span>
   <span class="font10">experienced </span>
   <span class="font10">impact </span>
   <span class="font10">improvement </span>
   <span class="font10">led </span>
   <span class="font10">local </span>
   <span class="font10">measure </span>
   <span class="font10">mg/ </span>
   <span class="font10">missing </span>
   <span class="font10">mydriasis </span>
   <span class="font10">patients, </span>
   <span class="font10">patients. </span>
   <span class="font10">presented </span>
   <span class="font10">rate </span>
   <span class="font10">severe </span>
   <span class="font10">showed </span>
   <span class="font10">solid; </span>
   <span class="font10">standard </span>
   <span class="font10">unilateral </span>
   <span class="font10">use </span>
   <span class="font10">values </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(sweating </span>
   <span class="font10">.‐. </span>
   <span class="font10">ASDD‐C, </span>
   <span class="font10">Brickell </span>
   <span class="font10">CDLQI </span>
   <span class="font10">CDLQI, </span>
   <span class="font10">Carlo </span>
   <span class="font10">Corporation; </span>
   <span class="font10">Daily </span>
   <span class="font10">Differences </span>
   <span class="font10">Disease </span>
   <span class="font10">Green </span>
   <span class="font10">LLC; </span>
   <span class="font10">Life </span>
   <span class="font10">MCMC, </span>
   <span class="font10">Patient </span>
   <span class="font10">Patients </span>
   <span class="font10">Pediatric </span>
   <span class="font10">Pharmaceuticals </span>
   <span class="font10">Pharmaceuticals, </span>
   <span class="font10">Post </span>
   <span class="font10">Sweating </span>
   <span class="font10">Vision </span>
   <span class="font10">administered </span>
   <span class="font10">administration </span>
   <span class="font10">approved </span>
   <span class="font10">bilateral </span>
   <span class="font10">bold </span>
   <span class="font10">children </span>
   <span class="font10">children's </span>
   <span class="font10">clinical </span>
   <span class="font10">courier; </span>
   <span class="font10">did </span>
   <span class="font10">differences. </span>
   <span class="font10">effects </span>
   <span class="font10">em; </span>
   <span class="font10">focal </span>
   <span class="font10">following </span>
   <span class="font10">generally </span>
   <span class="font10">honoraria </span>
   <span class="font10">hyperhidrosis, </span>
   <span class="font10">hyperhidrosis. </span>
   <span class="font10">impute </span>
   <span class="font10">included </span>
   <span class="font10">majority </span>
   <span class="font10">min </span>
   <span class="font10">once‐daily </span>
   <span class="font10">oral </span>
   <span class="font10">outcome </span>
   <span class="font10">patient‐reported </span>
   <span class="font10">pt;} </span>
   <span class="font10">randomized, </span>
   <span class="font10">reduction </span>
   <span class="font10">resolved </span>
   <span class="font10">review </span>
   <span class="font10">skipped </span>
   <span class="font10">small </span>
   <span class="font10">studies </span>
   <span class="font10">subgroups, </span>
   <span class="font10">subgroups. </span>
   <span class="font10">support </span>
   <span class="font10">treatment. </span>
   <span class="font10">treatment‐emergent </span>
   <span class="font10">trials. </span>
   <span class="font10">validated </span>
   <span class="font10">vehicle. </span>
   <span class="font10">‐point </span>
  </p>
 </body>
</html>
